| Trial ID: | L5780 |
| Source ID: | NCT02597309
|
| Associated Drug: |
Canagliflozin
|
| Title: |
The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin
|
| Acronym: |
I-Can
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes, Obesity
|
| Interventions: |
DRUG: Canagliflozin
|
| Outcome Measures: |
Primary: Reduction in insulin recuirement, Reduction in insulin requirements after adding canagliflozin with a difference in insulin dose of ≥30% between the 2 intervention groups, Twenty four weeks |
|
| Sponsor/Collaborators: |
Sponsor: Joslin Diabetes Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-11
|
| Completion Date: |
2017-07
|
| Results First Posted: |
|
| Last Update Posted: |
2017-03-01
|
| Locations: |
Joslin Diabetes Center, Boston, Massachusetts, 02215, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02597309
|
